Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyroglutamyl(3)-amyloid beta-protein (pE3-Aβ)
- Target
- pE3-Aβ
- Molecular classification
- Peptide, Modified Peptide, Amyloid beta peptide variant
01
Overview
Pyroglutamyl(3)-amyloid beta-protein represents an N-terminally truncated/modified variant central to Alzheimer’s pathogenesis due to its enhanced aggregation propensity, stability within plaques, potent neurotoxicity—especially when co-existing with other forms—and strong correlation with clinical symptoms. Its unique biochemical properties make it both a key biomarker candidate for diagnosis/prognosis as well as an attractive therapeutic target under active investigation.
- Other names
- AβpE3pE(3)-AβAβpE
02
Mechanism of action
Immunotherapies targeting pE3-Aβ (under investigation)
03
Biological functions
Protein aggregationNeurotoxicityAmyloid plaque formation
04
Disease associations
Alzheimer's DiseaseNeurodegenerative disease
05
Safety considerations
Incomplete understanding of underlying mechanisms of pE3-Aβ targeted therapiesPotential for off-target effects with immunotherapyChallenges in achieving successful clinical outcomes
06
Biomarkers
pE(3)-Aβ levels in brain tissueFrontal cortex pE(3)-Aβ load
Beyond the preview
Go deeper on Pyroglutamyl(3)-amyloid beta-protein (pE3-Aβ).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pyroglutamyl(3)-amyloid beta-protein (pE3-Aβ).